Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Immune Correlates of Disease Progression in Linked HIV-1 Infection.

Tuen M, Bimela JS, Banin AN, Ding S, Harkins GW, Weiss S, Itri V, Durham AR, Porcella SF, Soni S, Mayr L, Meli J, Torimiro JN, Tongo M, Wang X, Kong XP, Nádas A, Kaufmann DE, Brumme ZL, Nanfack AJ, Quinn TC, Zolla-Pazner S, Redd AD, Finzi A, Gorny MK, Nyambi PN, Duerr R.

Front Immunol. 2019 May 14;10:1062. doi: 10.3389/fimmu.2019.01062. eCollection 2019.

2.

Development of a Versatile, Near Full Genome Amplification and Sequencing Approach for a Broad Variety of HIV-1 Group M Variants.

Banin AN, Tuen M, Bimela JS, Tongo M, Zappile P, Khodadadi-Jamayran A, Nanfack AJ, Meli J, Wang X, Mbanya D, Ngogang J, Heguy A, Nyambi PN, Fokunang C, Duerr R.

Viruses. 2019 Apr 1;11(4). pii: E317. doi: 10.3390/v11040317.

3.

Short Communication: False Recent Ratio of the Limiting-Antigen Avidity Assay and Viral Load Testing Algorithm Among Cameroonians with Long-Term HIV Infection.

Lynch BA, Patel EU, Courtney CR, Nanfack AJ, Bimela J, Wang X, Eid I, Quinn TC, Laeyendecker O, Nyambi PN, Duerr R, Redd AD.

AIDS Res Hum Retroviruses. 2017 Nov;33(11):1114-1116. doi: 10.1089/AID.2017.0084. Epub 2017 Aug 7.

4.

Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.

Nanfack AJ, Redd AD, Bimela JS, Ncham G, Achem E, Banin AN, Kirkpatrick AR, Porcella SF, Agyingi LA, Meli J, Colizzi V, Nádas A, Gorny MK, Nyambi PN, Quinn TC, Duerr R.

J Clin Microbiol. 2017 Sep;55(9):2785-2800. doi: 10.1128/JCM.00634-17. Epub 2017 Jun 28.

5.

Contrasting antibody responses to intrasubtype superinfection with CRF02_AG.

Courtney CR, Mayr L, Nanfack AJ, Banin AN, Tuen M, Pan R, Jiang X, Kong XP, Kirkpatrick AR, Bruno D, Martens CA, Sykora L, Porcella SF, Redd AD, Quinn TC, Nyambi PN, Dürr R.

PLoS One. 2017 Mar 13;12(3):e0173705. doi: 10.1371/journal.pone.0173705. eCollection 2017.

6.

Monitoring HIV-1 Group M Subtypes in Yaoundé, Cameroon Reveals Broad Genetic Diversity and a Novel CRF02_AG/F2 Infection.

Courtney CR, Agyingi L, Fokou A, Christie S, Asaah B, Meli J, Ngai J, Hewlett I, Nyambi PN.

AIDS Res Hum Retroviruses. 2016 Apr;32(4):381-5. doi: 10.1089/aid.2015.0286. Epub 2015 Dec 17.

7.

Hepatitis B and C Co-Infections in Some HIV-Positive Populations in Cameroon, West Central Africa: Analysis of Samples Collected Over More Than a Decade.

Noubiap JJ, Aka PV, Nanfack AJ, Agyingi LA, Ngai JN, Nyambi PN.

PLoS One. 2015 Sep 15;10(9):e0137375. doi: 10.1371/journal.pone.0137375. eCollection 2015.

8.

Use of amplification refractory mutation system PCR assay as a simple and effective tool to detect HIV-1 drug resistance mutations.

Nanfack AJ, Agyingi L, Noubiap JJ, Ngai JN, Colizzi V, Nyambi PN.

J Clin Microbiol. 2015 May;53(5):1662-71. doi: 10.1128/JCM.00114-15. Epub 2015 Mar 18.

9.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. doi: 10.1093/infdis/jit114.

10.

Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus.

Mayr LM, Powell RL, Ngai JN, Takang WA, Nádas A, Nyambi PN.

PLoS One. 2012;7(6):e38989. doi: 10.1371/journal.pone.0038989. Epub 2012 Jun 14.

11.

CRF22_01A1 is involved in the emergence of new HIV-1 recombinants in Cameroon.

Zhao J, Tang S, Ragupathy V, Gaddam D, Wang X, Zhang P, Nyambi PN, Hewlett I.

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):344-50. doi: 10.1097/QAI.0b013e318258c7e3.

12.

Sequence analysis of the dimerization initiation site of concordant and discordant viral variants superinfecting HIV type 1 patients.

Mayr L, Powell R, Kinge T, Nyambi PN.

AIDS Res Hum Retroviruses. 2011 Nov;27(11):1231-5. doi: 10.1089/AID.2011.0010. Epub 2011 May 25.

13.

Absence of detectable xenotropic murine leukemia virus-related virus in plasma or peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected blood donors or individuals in Africa.

Tang S, Zhao J, Viswanath R, Nyambi PN, Redd AD, Dastyar A, Spacek LA, Quinn TC, Wang X, Wood O, Gaddam D, Devadas K, Hewlett IK.

Transfusion. 2011 Mar;51(3):463-8. doi: 10.1111/j.1537-2995.2010.02932.x. Epub 2010 Nov 15.

14.

Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus.

Powell RL, Kinge T, Nyambi PN.

J Virol. 2010 Sep;84(18):9415-26. doi: 10.1128/JVI.02732-09. Epub 2010 Jul 14.

15.

Characterization of immune responses to capsid protein p24 of human immunodeficiency virus type 1 and implications for detection.

Tang S, Zhao J, Wang A, Viswanath R, Harma H, Little RF, Yarchoan R, Stramer SL, Nyambi PN, Lee S, Wood O, Wong EY, Wang X, Hewlett IK.

Clin Vaccine Immunol. 2010 Aug;17(8):1244-51. doi: 10.1128/CVI.00066-10. Epub 2010 Jun 9.

16.

Longitudinal quasispecies analysis of viral variants in HIV type 1 dually infected individuals highlights the importance of sequence identity in viral recombination.

Powell RL, Lezeau L, Kinge T, Nyambi PN.

AIDS Res Hum Retroviruses. 2010 Mar;26(3):253-64. doi: 10.1089/aid.2009.0174.

17.

HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naïve to HAART in Cameroon.

Burda ST, Viswanath R, Zhao J, Kinge T, Anyangwe C, Tinyami ET, Haldar B, Powell RL, Jarido V, Hewlett IK, Nyambi PN.

J Med Virol. 2010 Feb;82(2):187-96. doi: 10.1002/jmv.21677.

18.

High frequency of HIV-1 dual infections among HIV-positive individuals in Cameroon, West Central Africa.

Powell RL, Urbanski MM, Burda S, Kinge T, Nyambi PN.

J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):84-92. doi: 10.1097/QAI.0b013e31818d5a40.

PMID:
19295338
19.

A heteroduplex assay for the rapid detection of dual Human Immunodeficiency Virus Type 1 infections.

Powell RL, Urbanski MM, Nyambi PN.

J Virol Methods. 2008 Apr;149(1):20-7. doi: 10.1016/j.jviromet.2008.01.015. Epub 2008 Mar 7.

20.

Utility of the heteroduplex assay (HDA) as a simple and cost-effective tool for the identification of HIV type 1 dual infections in resource-limited settings.

Powell RL, Urbanski MM, Burda S, Nanfack A, Kinge T, Nyambi PN.

AIDS Res Hum Retroviruses. 2008 Jan;24(1):100-5. doi: 10.1089/aid.2007.0162.

PMID:
18275354
21.

Identification of a novel circulating recombinant form (CRF) 36_cpx in Cameroon that combines two CRFs (01_AE and 02_AG) with ancestral lineages of subtypes A and G.

Powell RL, Zhao J, Konings FA, Tang S, Nanfack A, Burda S, Urbanski MM, Saa DR, Hewlett I, Nyambi PN.

AIDS Res Hum Retroviruses. 2007 Aug;23(8):1008-19.

PMID:
17725418
22.

Circulating recombinant form (CRF) 37_cpx: an old strain in Cameroon composed of diverse, genetically distant lineages of subtypes A and G.

Powell RL, Zhao J, Konings FA, Tang S, Ewane L, Burda S, Urbanski MM, Saa DR, Hewlett I, Nyambi PN.

AIDS Res Hum Retroviruses. 2007 Jul;23(7):923-33.

PMID:
17678477
23.

Quasispecies analysis of novel HIV-1 recombinants of subtypes A and G reveals no similarity to the mosaic structure of CRF02_AG.

Powell RL, Konings FA, Nanfack A, Burda S, Urbanski MM, Saa D, Nyambi PN.

J Med Virol. 2007 Sep;79(9):1270-85.

PMID:
17607774
24.

Genetic analysis of HIV-1 strains in rural eastern Cameroon indicates the evolution of second-generation recombinants to circulating recombinant forms.

Konings FA, Haman GR, Xue Y, Urbanski MM, Hertzmark K, Nanfack A, Achkar JM, Burda ST, Nyambi PN.

J Acquir Immune Defic Syndr. 2006 Jul;42(3):331-41.

PMID:
16639350
25.
26.

Human immunodeficiency virus (HIV) reverse transcriptase activity correlates with HIV RNA load: implications for resource-limited settings.

Sivapalasingam S, Essajee S, Nyambi PN, Itri V, Hanna B, Holzman R, Valentine F.

J Clin Microbiol. 2005 Aug;43(8):3793-6.

27.

HIV-1 CRF09_cpx circulates in the North West Province of Cameroon where CRF02_AG infections predominate and recombinant strains are common.

Burda ST, Konings FA, Williams CA, Anyangwe C, Nyambi PN.

AIDS Res Hum Retroviruses. 2004 Dec;20(12):1358-63.

PMID:
15650429
29.
30.

Infection with HIV type 1 group M non-B subtypes in individuals living in New York City.

Achkar JM, Burda ST, Konings FA, Urbanski MM, Williams CA, Seifen D, Kahirimbanyi MN, Vogler M, Parta M, Lupatkin HC, Zolla-Pazner S, Nyambi PN.

J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):835-44.

PMID:
15213568
31.

Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon.

Konings FA, Zhong P, Agwara M, Agyingi L, Zekeng L, Achkar JM, Ewane L, Saa, Afane Ze E, Kinge T, Nyambi PN.

AIDS Res Hum Retroviruses. 2004 Jan;20(1):105-9.

PMID:
15008125
32.

Defining human immunodeficiency virus (HIV) type 1 immunotypes with six human monoclonal antibodies.

Nádas A, Zhong P, Burda S, Zekeng L, Urbanski M, Gorny MK, Zolla-Pazner S, Nyambi PN.

AIDS Res Hum Retroviruses. 2004 Jan;20(1):55-65.

PMID:
15000699
33.

The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, Anyangwe CA, Krachmarov C, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S.

J Virol. 2004 Mar;78(5):2394-404.

34.

Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades.

Mbah HA, Burda S, Gorny MK, Williams C, Revesz K, Zolla-Pazner S, Nyambi PN.

J Virol. 2001 Aug;75(16):7785-8.

35.

A virus binding assay for studying the antigenic landscape on intact, native, primary human immunodeficiency virus-type 1.

Nyambi PN, Burda S, Bastiani L, Williams C.

J Immunol Methods. 2001 Jul 1;253(1-2):253-62.

PMID:
11384686
36.

Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.

York J, Follis KE, Trahey M, Nyambi PN, Zolla-Pazner S, Nunberg JH.

J Virol. 2001 Mar;75(6):2741-52.

37.

Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.

Nyambi PN, Nádas A, Mbah HA, Burda S, Williams C, Gorny MK, Zolla-Pazner S.

J Virol. 2000 Nov;74(22):10670-80.

38.

Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.

Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nádas A, Zolla-Pazner S.

J Virol. 2000 Aug;74(15):7096-107.

39.

The implications of antigenic diversity for vaccine development.

Zolla-Pazner S, Gomy MK, Nyambi PN.

Immunol Lett. 1999 Mar;66(1-3):159-64. Review.

PMID:
10203049
40.

Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.

Zolla-Pazner S, Gorny MK, Nyambi PN, VanCott TC, Nádas A.

J Virol. 1999 May;73(5):4042-51.

41.

Genetic variation of HIV type 1: relevance of interclade variation to vaccine development.

van der Groen G, Nyambi PN, Beirnaert E, Davis D, Fransen K, Heyndrickx L, Ondoa P, Van der Auwera G, Janssens W.

AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S211-21. Review.

PMID:
9814946
42.
43.

Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant.

Nyambi PN, Lewi P, Peeters M, Janssens W, Heyndrickx L, Fransen K, Andries K, Vanden Haesevelde M, Heeney J, Piot P, van der Groen G.

J Virol. 1997 Mar;71(3):2320-30.

44.

The neutralization relationship of HIV type 1, HIV type 2, and SIVcpz is reflected in the genetic diversity that distinguishes them.

Nyambi PN, Willems B, Janssens W, Fransen K, Nkengasong J, Peeters M, Vereecken K, Heyndrickx L, Piot P, van der Groen G.

AIDS Res Hum Retroviruses. 1997 Jan 1;13(1):7-17.

PMID:
8989422
45.

Multivariate analysis of human immunodeficiency virus type 1 neutralization data.

Nyambi PN, Nkengasong J, Lewi P, Andries K, Janssens W, Fransen K, Heyndrickx L, Piot P, van der Groen G.

J Virol. 1996 Sep;70(9):6235-43.

46.

Mother-to-child transmission of human T-cell lymphotropic virus types I and II (HTLV-I/II) in Gabon: a prospective follow-up of 4 years.

Nyambi PN, Ville Y, Louwagie J, Bedjabaga I, Glowaczower E, Peeters M, Kerouedan D, Dazza M, Larouze B, van der Groen G, Delaporte E.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):187-92.

PMID:
8680891
47.

Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses.

Nyambi PN, Nkengasong J, Peeters M, Simon F, Eberle J, Janssens W, Fransen K, Willems B, Vereecken K, Heyndrickx L, et al.

J Infect Dis. 1995 Nov;172(5):1228-37.

PMID:
7594658
48.

Detection of human immunodeficiency virus type 1 (HIV-1) in heel prick blood on filter paper from children born to HIV-1-seropositive mothers.

Nyambi PN, Fransen K, De Beenhouwer H, Chomba EN, Temmerman M, Ndinya-Achola JO, Piot P, van der Groen G.

J Clin Microbiol. 1994 Nov;32(11):2858-60.

Supplemental Content

Loading ...
Support Center